After rounding up a long lineup of collaborations for its cancer vaccine axalimogene filolisbac (ADXS-HPV), Advaxis says that a small study for cervical cancer produced promising outcomes for a significant number of the 26 patients involved.
That assessment was initially spurned by the market, with the stock ($ADXS) plunging close to 30% before immediately bouncing back and hovering around even Thursday afternoon.
The therapeutic vaccine was put through its paces among patients who had already failed at least one treatment. On average, says the Princeton, NJ-based biotech, these patients would have around 4 to 7 months to live, with no viable treatment options. But after 12 months of therapy in the single arm study--where there was no comparator arm--the investigators tracked a 38.5% survival rate.
The data come from the first stage of a two-step Phase II study, which the biotech says should open a path to establishing a special protocol assessment for a Phase III study.
Read the full article here